C0444008||Human Leucocyte Antigen B50
C0751339||Generalized Myasthenia Gravis
C0751340||Pure Ocular
C0008972||study
C0024518||major histocompatibility complex
C0024518||major histocompatibility complex
C0017355||class I
C0017349||II alleles
C0549217||Turkish
C0026896||myasthenia gravis
C0026896||myasthenia gravis
C0024518||major histocompatibility complex
C0017355||class I
C0017349||II alleles
C0026896||myasthenia gravis
C1285573||genotyped
C0019721||human leucocyte antigen
C0019721||human leucocyte antigen
C0026896||myasthenia gravis
C1515021||subgroups
C0026896||myasthenia gravis
C0439745||grouped
C0062847||HLA-B*61
C0062856||C*05
C0026896||myasthenia gravis
C1515021||Subgroup
C0936012||analyses
C0002085||HLA-DRB1*14
C0002085||DQB1*02 alleles
C1833334||early-onset
C0026896||myasthenia gravis
C0236516||anti-AchR antibodies
C0062856||C*05
C0062856||HLA-C*05
C1566853||DRB1*01
C1699878||DRB1*11
C0751340||ocular MG
C0019728||HLA-A*01
C0121978||A*31
C0019737||B*08
C0122040||DRB1*14
C0040115||thymic hyperplasia
C0122020||DQB1*03
C0002085||allele
C0040100||thymoma
C0751339||generalized MG
C0751340||pure ocular
C1457887||symptoms
C0002085||HLA-B*50 allele
C0849867||generalized disease
C0751340||pure ocular
C1457887||symptoms
C0699748||pathogenesis
C0026896||myasthenia gravis